Publikationen, an denen er mitarbeitet Patricia Ruiz Garbajosa (79)

2024

  1. A long-term survey of Serratia spp. bloodstream infections revealed an increase of antimicrobial resistance involving adult population

    Microbiology Spectrum, Vol. 12, Núm. 2

  2. Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Escherichia coli isolates with KPC-3 mutants and application of FTIR biotyping

    Microbiology Spectrum, Vol. 12, Núm. 4

  3. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 69-77

2023

  1. Automatic Discrimination of Species within the Enterobacter cloacae Complex Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Supervised Algorithms

    Journal of clinical microbiology, Vol. 61, Núm. 4, pp. e0104922

  2. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 6, pp. 360-370

  3. Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 5, pp. 1259-1264

  4. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

  5. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project)

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2291-2296

  6. Treatment guidelines for multidrug-resistant Gram-negative microorganisms

    Revista Espanola de Quimioterapia, Vol. 36, pp. 46-51

2022

  1. Antibacterial spectrum of cefiderocol

    Revista Espanola de Quimioterapia, Vol. 35, pp. 20-27

  2. Carbapenemase-producing Enterobacterales infections in COVID-19 patients

    Infectious Diseases, Vol. 54, Núm. 1, pp. 36-45

  3. Correction to: Evaluation of CHROMagar™-Serratia agar, a new chromogenic medium for the detection and isolation of Serratia marcescens (European Journal of Clinical Microbiology & Infectious Diseases, (2021), 40, 12, (2593-2596), 10.1007/s10096-021-04328-w)

    European Journal of Clinical Microbiology and Infectious Diseases

  4. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection

    Journal of clinical microbiology, Vol. 60, Núm. 3, pp. e0224521

  5. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3

2021

  1. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2677-2699

  2. Characterization of carbapenemase-producing Serratia marcescens and whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016-18)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 1, pp. 110-116

  3. Covid-19: Impact on prescribing and antimicrobial resistance

    Revista Espanola de Quimioterapia, Vol. 34, pp. 63-68

  4. Emergence and Persistence over Time of Carbapenemase-Producing Enterobacter Isolates in a Spanish University Hospital in Madrid, Spain (2005-2018)

    Microbial Drug Resistance, Vol. 27, Núm. 7, pp. 895-903

  5. Emergence of the new kpc-49 variant conferring an esbl phenotype with resistance to ceftazidime-avibactam in the st131-h30r1 escherichia coli high-risk clone

    Pathogens, Vol. 10, Núm. 1, pp. 1-10

  6. Etiology and antimicrobial susceptibility profiles of anaerobic bacteria isolated from clinical samples in a university hospital in Madrid, Spain

    Anaerobe, Vol. 72